Optimizing Bispecific Antibody Therapy in Late-Line Multiple Myeloma: Expanding Clinical Use vs Addressing Toxicity Concerns

Join Dr Beth Faiman as she leads an engaging debate between Charise Gleason and Donna Catamero on optimizing bispecific antibody therapy in relapsed or refractory multiple myeloma, balancing expanded clinical use with safety and toxicity concerns. 

Introduction:

Dr Beth Faiman introduces key principles for selecting relapsed multiple myeloma treatment and sets the stage for a dynamic discussion on the evolving role of bispecific antibodies in outpatient care.

Round 1:

In Round 1, Charise Gleason argues that step-up dosing and adverse event prophylaxis can safely expand bispecific antibody use in outpatient settings, while Donna Catamero highlights ongoing toxicity risks that may limit wider adoption.

Round 2:

In Round 2, Charise Gleason emphasizes how effective adverse event (AE) management and workflow coordination can support broader bispecific antibody adoption, whereas Donna Catamero counters with evidence of residual risk and cumulative adverse event burdens that still challenge outpatient feasibility.

Round 3:

In Round 3, Charise Gleason highlights how structured outpatient protocols and patient selection can enable safe community adoption of bispecific antibody therapy, while Donna Catamero cautions that cumulative immunosuppression, staffing demands and limited resources may hinder sustainable implementation in real-world practice.